VERAXA Biotech Shareholders Overwhelmingly Approve Strategic Measures

VERAXA Biotech (NASDAQ: VRXA) has secured overwhelming shareholder approval for key corporate governance and financing measures, with over 99.94% of votes in favor and 72.20% of outstanding shares represented at its Extraordinary General Meeting. The approved proposals include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through December 31, 2030, and an expansion of the board of directors from five to seven members. This strong mandate reflects investor confidence in VERAXA’s strategic direction as it advances its antibody-based cancer therapeutics pipeline.

The enhanced framework is designed to support VERAXA’s long-term growth by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, and capital markets activities. Management emphasized that the vote underscores shareholder alignment with the company’s focus on developing its proprietary BiTAC(R) technology platform, which includes bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. VERAXA’s pipeline is rooted in scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned institution in life science research.

For investors seeking the latest updates, the company’s newsroom at http://ibn.fm/VRXA provides ongoing information. The announcement was disseminated via MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. MissionIR leverages a vast network of wire solutions via InvestorWire and editorial syndication to over 5,000 outlets to enhance visibility for companies in the investment community.